Amgen, Daiichi Sankyo In Japanese Commercialization Deal

Thousand Oaks-based Amgen and Daiichi Sankyo Company said late Wednesday evening, that the two have reached an agreement to commercialize biosimilars in Japan. The two said the deal covers several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Financial terms of the deal were not disclosed. The two said Amgen will remain responsible for the development and manufacturing of the biosimilars, while Daiichi Sankyo will be responsible for marketing approval, distribution, and commercialization in Japan.